

# Petr Arenberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4693949/publications.pdf>

Version: 2024-02-01

111  
papers

7,579  
citations

159585

30  
h-index

53230

85  
g-index

114  
all docs

114  
docs citations

114  
times ranked

9653  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1782-1783.	2.2	2
2	Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic. <i>Central European Journal of Public Health</i> , 2022, 30, 46-50.	1.1	1
3	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	2.8	102
4	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSGURE study*. <i>British Journal of Dermatology</i> , 2021, 184, 425-436.	1.5	36
5	Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. <i>British Journal of Dermatology</i> , 2021, 184, 966-967.	1.5	17
6	European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 27-49.	2.4	28
7	Improvement of atopic dermatitis and IgA nephropathy in a patient treated by dupilumab. <i>Dermatologic Therapy</i> , 2021, 34, e14708.	1.7	2
8	Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. <i>Journal of Dermatological Treatment</i> , 2021, 32, 164-173.	2.2	15
9	Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e381-e383.	2.4	4
10	Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. <i>Dermatologic Therapy</i> , 2021, 34, e14849.	1.7	9
11	Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic. <i>Dermatology and Therapy</i> , 2021, 11, 543-553.	3.0	6
12	Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab. <i>British Journal of Dermatology</i> , 2021, 184, e195.	1.5	4
13	Alopecia barbae severity score: A novel scoring system to estimate the extent of beard loss and success of treatment. <i>British Journal of Dermatology</i> , 2021, 185, 847-849.	1.5	1
14	Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic. <i>Dermatology and Therapy</i> , 2021, 11, 1345-1355.	3.0	29
15	Acrodermatitis continua Hallopeau successfully treated by risankizumab. <i>International Journal of Dermatology</i> , 2021, 60, e144-e145.	1.0	3
16	Dead Sea climatotherapy versus topical steroid treatment for atopic dermatitis children: long-term follow-up study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 711-715.	2.2	4
17	Palladium causes bizarre skin hyperpigmentation in long-term dihydrocodeinone –Braun™ abusers. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 188-191.	2.4	4
18	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154

#	ARTICLE	IF	CITATIONS
19	European dermatology forum " updated guidelines on the use of extracorporeal photopheresis 2020 " part 1. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2693-2716.	2.4	49
20	Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study. Dermatologic Therapy, 2020, 33, e14110.	1.7	5
21	The evolving field of Dermatocancerology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22
22	Darier disease complicated by severe Kaposi varicelliform eruption resistant to acyclovir. Dermatologic Therapy, 2020, 33, e14500.	1.7	0
23	Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e281-e283.	2.4	6
24	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics " Update 2019. European Journal of Cancer, 2020, 126, 141-158.	2.8	133
25	Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. International Journal of Dermatology, 2020, 59, 733-735.	1.0	17
26	Answer to the comment by Plachouri et al. on the necessity for adequate training of European dermatology residents in skin of colour. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e597-e598.	2.4	0
27	Unusual periungual nodulocystic lesions leading to the diagnosis of extranodal marginal zone lymphoma. Indian Journal of Dermatology, 2020, 65, 83.	0.3	0
28	Training requirements and recommendation for the specialty of dermatology and venereology European Standards of Postgraduate Medical Specialist Training. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 3-25.	2.4	6
29	Deroofing mit anschlieãender sorgfãltiger Sinustrakt-Exzision: ein modifizierter chirurgischer Ansatz bei Hidradenitis suppurativa. JDDG - Journal of the German Society of Dermatology, 2019, 17, 698-702.	0.8	1
30	Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. JDDG - Journal of the German Society of Dermatology, 2019, 17, 698-702.	0.8	16
31	The role of the dermatologist in the immune-mediated/allergic diseases " position statement of the EADV task force on contact dermatitis, EADV task force on occupational skin diseases, UEMS EBDV subcommission allergology and European Dermatology Forum. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1459-1464.	2.4	0
32	Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). European Journal of Cancer, 2019, 114, 117-127.	2.8	120
33	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. British Journal of Dermatology, 2019, 181, 954-966.	1.5	84
34	Targeted treatment of metastatic melanoma in a drug-addicted patient with pre-existing hepatitis C. Dermatologic Therapy, 2019, 32, e12790.	1.7	2
35	Increased sensitivity and high specificity of indirect immunofluorescence in detecting IgG subclasses for diagnosis of bullous pemphigoid. Clinical and Experimental Dermatology, 2018, 43, 248-253.	1.3	9
36	Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. Journal of Dermatological Treatment, 2018, 29, 579-582.	2.2	5

#	ARTICLE	IF	CITATIONS
37	Comparative Study with a Lip Balm Containing 0.5% Propolis Special Extract GH 2002 versus 5% Aciclovir Cream in Patients with Herpes Labialis in the Papular/Erythematous Stage: A Single-blind, Randomized, Two-arm Study. <i>Current Therapeutic Research</i> , 2018, 88, 1-7.	1.2	14
38	Multiple switches between <scp>GP</scp>2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory <scp>EGALITY</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 420-427.	2.4	70
39	Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e72-e74.	2.4	5
40	Scalp melanoma after antihair loss mesotherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e187-e188.	2.4	6
41	Current therapeutical options in primary cutaneous T-cell lymphomas. <i>Dermatologie Pro Praxi</i> , 2018, 12, 31-35.	0.0	1
42	Characteristics and risk profile of psoriasis patients included in the Czech national registry <scp>BIOREP</scp> and a comparison with other registries. <i>International Journal of Dermatology</i> , 2017, 56, 428-434.	1.0	18
43	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
44	Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. <i>Dermatologic Therapy</i> , 2017, 30, e12522.	1.7	8
45	New and current preventive treatment options in actinic keratosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 13-17.	2.4	25
46	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. <i>European Journal of Cancer</i> , 2017, 86, 334-348.	2.8	212
47	Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e253-e254.	2.4	16
48	Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study. <i>Journal of Dermatology</i> , 2017, 44, 363-369.	1.2	25
49	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 928-938.	1.5	155
50	Melanoma antigens are biomarkers for ipilimumab response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 252-259.	2.4	9
51	Severe diclofenac photoallergy in a patient treated with vemurafenib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 713-715.	2.4	3
52	Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1626-1627.	2.4	3
53	Severe exacerbation of psoriasis after intravenous immunoglobulin in patient with multiple sclerosis that started during biologic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 355-356.	2.4	3
54	Dead Sea ultraviolet climatotherapy for children with atopic dermatitis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2016, 32, 254-261.	1.5	7

#	ARTICLE	IF	CITATIONS
55	FRI0460â€¦Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 603.2-604.	0.9	9
56	Quantitative changes of melanomaâ€¦associated antigens as a biomarker for targeted therapy response. <i>Experimental Dermatology</i> , 2016, 25, 727-729.	2.9	1
57	Phase 3 evaluation of HP802â€¦247 in the treatment of chronic venous leg ulcers. <i>Wound Repair and Regeneration</i> , 2016, 24, 894-903.	3.0	24
58	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	2.4	41
59	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 386, 552-561.	13.7	350
60	European S3â€¦Guidelines on the systemic treatment of psoriasis vulgaris â€œ Update 2015 â€œ Short version â€œ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	2.4	353
61	A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2063-2064.	2.4	10
62	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	3.9	21
63	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and) Tj ETQq1 1.0,784314 rgBT / 13.7 7198	13.7	7198
64	Expected outcomes from topical haemoglobin spray in non-healing and worsening venous leg ulcers. <i>Journal of Wound Care</i> , 2015, 24, 228-236.	1.2	8
65	Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 562-568.	0.6	6
66	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>Cerebrovascular Diseases</i> , 2014, 38, 176-181.	1.7	24
67	Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet, The</i> , 2014, 384, 2036-2045.	13.7	124
68	Guidelines on the use of extracorporeal photopheresis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-37.	2.4	212
69	Management of psoriasis vulgaris and multiple sclerosis with fumaric acid. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e60-e61.	1.2	8
70	Malignant melanoma in the Czech Republic: Incidence and mortality according to sex, age and disease stage. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2014, 158, 438-446.	0.6	9
71	The HLA-Cw*06 allele and âˆ’1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population. <i>Rheumatology International</i> , 2013, 33, 913-919.	3.0	9
72	JDDG - the first English print version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 278a-278b.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Incidence of cutaneous malignant melanoma in the Czech Republic: The risks of sun exposure for adolescents. <i>Neoplasma</i> , 2012, 59, 316-325.	1.6	10
74	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	27.0	511
75	Light-activated nanofibre textiles exert antibacterial effects in the setting of chronic wound healing. <i>Experimental Dermatology</i> , 2012, 21, 619-624.	2.9	60
76	Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis. <i>Journal of Dermatology</i> , 2012, 39, 0-0.	1.2	1
77	Effect of topical heparin and levomenol on atopic dermatitis: a randomized four-arm, placebo-controlled, double-blind clinical study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 688-694.	2.4	15
78	Temporal arteritis with scalp ulceration and blindness. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 50-52.	0.8	2
79	New developments in fluorescence diagnostics. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 368-372.	0.8	4
80	Neue Entwicklungen in der Fluoreszenzdiagnostik. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 368-373.	0.8	1
81	Eruptive multiple Spitz nevi in a patient with epilepsy and drug addiction. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, , no-no.	0.8	0
82	Acute bronchitis therapy with ivy leaves extracts in a two-arm study. A double-blind, randomised study vs. an other ivy leaves extract. <i>Phytomedicine</i> , 2011, 18, 1105-1109.	5.3	60
83	Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011, 303, 1-10.	1.9	690
84	Quality of Life in Patients with Uraemic Xerosis and Pruritus. <i>Acta Dermato-Venereologica</i> , 2011, 91, 313-317.	1.3	53
85	Quantitative detection of melanoma-associated antigens by multimarker real-time RT-PCR for molecular staging: results of a 5-year study. <i>Experimental Dermatology</i> , 2010, 19, 994-999.	2.9	13
86	Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. <i>International Journal of Dermatology</i> , 2010, 49, 1445-1449.	1.0	46
87	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. <i>British Journal of Dermatology</i> , 2010, 163, 402-411.	1.5	99
88	Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of <i>Treponema pallidum</i> subsp. <i>pallidum</i> . <i>Journal of Medical Microbiology</i> , 2009, 58, 832-836.	1.8	104
89	Photodynamic Therapy of <i>Necrobiosis Lipoidica</i> – A Multicenter Study of 18 Patients. <i>Dermatology</i> , 2009, 218, 136-139.	2.1	55
90	Confocal laser-scanning capillaroscopy: a novel approach to the analysis of skin capillaries in vivo. <i>Skin Research and Technology</i> , 2009, 15, 476-481.	1.6	20

#	ARTICLE	IF	CITATIONS
91	The treatment of unilesional mycosis fungoides with methyl aminolevulinateâ€photodynamic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1134-1135.	2.4	4
92	Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 742-750.	5.7	211
93	Successful radiotherapy of facial angiosarcoma. <i>International Journal of Dermatology</i> , 2008, 47, 1190-1192.	1.0	12
94	Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 22, 070806223155002-???	2.4	16
95	Towards optimization of an organotypic assay system that imitates human hair follicle-like epithelial-mesenchymal interactions. <i>British Journal of Dermatology</i> , 2004, 151, 753-765.	1.5	56
96	Gene expression in actinic keratoses: pharmacological modulation by imiquimod. <i>British Journal of Dermatology</i> , 2004, 151, 1150-1159.	1.5	33
97	Tissue-engineered skin in the treatment of vitiligo lesions. <i>Folia Biologica</i> , 2000, 46, 157-60.	0.6	0
98	Ï‰-3 Fatty acidâ€based lipid infusion in patients with chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, multicenter trial. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 539-547.	1.2	128
99	Substance P binding in normal neonatal foreskin. <i>British Journal of Dermatology</i> , 1995, 132, 54-58.	1.5	10
100	The Lipoxygenase Inhibitor 2-Phenylmethyl-1-Naphthol (DuP 654) Is a 12(S)-Hydroxyeicosatetraenoic Acid Receptor Antagonist in the Human Epidermal Cell Line SCL-II. <i>Skin Pharmacology and Physiology</i> , 1993, 6, 148-151.	2.5	6
101	Characterization of high-affinity 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) binding sites on normal human keratinocytes. <i>Epithelial Cell Biology</i> , 1993, 2, 1-6.	0.1	1
102	Interleukin-8 receptor-mediated chemotaxis of normal human epidermal cells. <i>FEBS Letters</i> , 1992, 305, 241-243.	2.8	104
103	Defect of epidermal 12(S)-hydroxyeicosatetraenoic acid receptors in psoriasis. <i>European Journal of Clinical Investigation</i> , 1992, 22, 235-243.	3.4	11
104	Langerhans cells of the human skin possess high-affinity 12(S)-hydroxyeicosa tetraenoic acid receptors. <i>European Journal of Immunology</i> , 1992, 22, 2469-2472.	2.9	16
105	Interleukin-8 receptors in normal and psoriatic polymorphonuclear leukocytes. <i>Acta Dermato-Venereologica</i> , 1992, 72, 334-6.	1.3	1
106	Effect of Ciclosporin on Epidermal 12(S)-Hydroxyeicosatetraenoic Acid Binding Sites. <i>Skin Pharmacology and Physiology</i> , 1991, 4, 272-277.	2.5	5
107	Inhibition of 12(S)-Hydroxyeicosatetraenoic Acid [12(S)-HETE] Binding to Epidermal Cells by Ultraviolet-B. <i>Journal of Investigative Dermatology</i> , 1991, 97, 1028-1031.	0.7	5
108	Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line. <i>Archives of Dermatological Research</i> , 1991, 283, 333-336.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Cultivation of psoriatic keratinocytes and an attempt to isolate and detect a specific psoriatic antigen. Folia Biologica, 1991, 37, 52-4.	0.6	0
110	Urinary Tract Desquamation in Psoriasis. Dermatology, 1990, 180, 112-112.	2.1	1
111	Regulation of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) binding sites on human epidermal cells by interferon- $\beta$ . Experimental Cell Research, 1990, 191, 204-208.	2.6	15